Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IPOs and the New FDA

This article was originally published in RPM Report

Executive Summary

Ironwood Pharmaceuticals and Anthera Pharmaceuticals tested the public offering market in early 2010. The two companies share a positive reading on a thaw in the freeze on public financings, but they show different attitudes on the nature of the regulatory climate. To Ironwood, past regualtory difficulties for other companies are an opportunity. Ironwood does not see much of a threat from new FDA safety tools. Anthera sees the threat but says it has a plan to navigate the new authorities.

You may also be interested in...

Entering the World of REMS: Entereg Sets New Standard

Entereg is the most important new drug approved by FDA so far in 2008. Not because of its commercial prospects, which are far more limited than development partners GSK and Adolor once hoped for, but because it is a precedent-setting use of the agency's new drug safety authorities-and a case study in how those new tools can save a drug that might otherwise never have been marketed at all.

Aducanumab And The US Pricing Debate: A New Hook, But Still A Fuzzy Picture

Some Democratic senators are not fans of FDA’s approval of Biogen/Eisai’s Aduhelm, and are even more critical of the price of the Alzheimer’s therapy. That is providing a new hook to urge action on creating a federal price ‘negotiation’ program – but not any more clarity on a viable path to enacting one.

US FDA Drug Center Director Cavazzoni’s Top Priority: Winning ‘Hearts And Minds’

Patrizia Cavazzoni, FDA Center for Drug Evaluation and Research director, knows she has ‘huge shoes’ to fill. Convincing the CDER staff that she is capable of doing so is job one.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts